Intra-Cellular Therapies (Intra-Cellular Therapies) EV-to-EBITDA

Intra-Cellular Therapies Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBITDA							-11.10	-8.37	-13.67	-16.91	-40.43

Intra-Cellular Therapies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA																-16.91	-19.52	-28.22	-26.35	-40.43

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's EV-to-EBITDA falls into.

Intra-Cellular Therapies EV-to-EBITDA Calculation

Intra-Cellular Therapies's EV-to-EBITDA for today is calculated as:

Intra-Cellular Therapies's current Enterprise Value is $6,541.3 Mil.
Intra-Cellular Therapies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-158.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intra-Cellular Therapies  (NAS:ITCI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Intra-Cellular Therapies's PE Ratio for today is calculated as:

Intra-Cellular Therapies's share price for today is $72.37.
Intra-Cellular Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.460.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Intra-Cellular Therapies EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies (Intra-Cellular Therapies) Business Description